Mirna Adds Board Member
This article was originally published in Scrip
Mirna Therapeutics, a company focused on microRNA-based oncology therapeutics, has appointed Peter Greenleaf to its board of directors. Greenleaf has more than 20 years’ experience in drug development and commercialization and is currently chair and CEO of Sucampo Pharmaceuticals, Inc. Prior to this, he was CEO and a board member at Histogenics Corporation and previously served as president of AstraZeneca’s biologics arm, MedImmune LLC.